$BLUE
bluebird bio, Inc.

2013 Q2 Form 10-Q Financial Statement

#000119312513334653 Filed on August 14, 2013

View on sec.gov

Income Statement

Concept 2013 Q2 2012 Q2
Revenue $6.334M $85.00K
YoY Change 7351.76%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.300M $1.300M
YoY Change 153.85%
% of Gross Profit
Research & Development $7.247M $3.354M
YoY Change 116.07%
% of Gross Profit
Depreciation & Amortization $160.0K $70.00K
YoY Change 128.57%
% of Gross Profit
Operating Expenses $7.247M $3.354M
YoY Change 116.07%
Operating Profit -$4.194M -$4.600M
YoY Change -8.83%
Interest Expense -$400.0K $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net -$389.0K $37.00K
YoY Change -1151.35%
Pretax Income -$4.583M -$4.600M
YoY Change -0.37%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$4.583M -$4.563M
YoY Change 0.44%
Net Earnings / Revenue -72.36% -5368.24%
Basic Earnings Per Share -$23.21
Diluted Earnings Per Share -$2.091M -$23.21
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q2 2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $228.8M
YoY Change
Cash & Equivalents $228.8M $18.42M
Short-Term Investments
Other Short-Term Assets $1.700M
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $230.5M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $2.515M
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.500M
YoY Change
Total Long-Term Assets $4.018M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $230.5M
Total Long-Term Assets $4.018M
Total Assets $234.5M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.609M
YoY Change
Accrued Expenses $3.400M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $30.36M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $42.90M
YoY Change
Total Long-Term Liabilities $42.90M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $30.36M
Total Long-Term Liabilities $42.90M
Total Liabilities $73.27M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$84.48M
YoY Change
Common Stock $236.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $161.3M
YoY Change
Total Liabilities & Shareholders Equity $234.5M
YoY Change

Cashflow Statement

Concept 2013 Q2 2012 Q2
OPERATING ACTIVITIES
Net Income -$4.583M -$4.563M
YoY Change 0.44%
Depreciation, Depletion And Amortization $160.0K $70.00K
YoY Change 128.57%
Cash From Operating Activities -$8.250M -$3.990M
YoY Change 106.77%
INVESTING ACTIVITIES
Capital Expenditures -$460.0K -$180.0K
YoY Change 155.56%
Acquisitions
YoY Change
Other Investing Activities -$1.250M $0.00
YoY Change
Cash From Investing Activities -$1.710M -$180.0K
YoY Change 850.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 107.0M 10.00K
YoY Change 1069600.0%
NET CHANGE
Cash From Operating Activities -8.250M -3.990M
Cash From Investing Activities -1.710M -180.0K
Cash From Financing Activities 107.0M 10.00K
Net Change In Cash 97.01M -4.160M
YoY Change -2431.97%
FREE CASH FLOW
Cash From Operating Activities -$8.250M -$3.990M
Capital Expenditures -$460.0K -$180.0K
Free Cash Flow -$7.790M -$3.810M
YoY Change 104.46%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
24209000
CY2013Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2013Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2013Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
23721219 shares
CY2012Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18423000
CY2013Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23603000 shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
21511000 shares
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1190000 shares
CY2013Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23603000 shares
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.67
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3890000 shares
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
3.66
CY2013Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
440000 shares
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3856000 shares
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.08
CY2013Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2013Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2013Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
2582000
CY2013Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
245515000
CY2013Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1609000
CY2013Q2 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
2739000
CY2013Q2 us-gaap Liabilities Current
LiabilitiesCurrent
30358000
CY2013Q2 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
12155000
CY2013Q2 us-gaap Stockholders Equity
StockholdersEquity
161270000
CY2013Q2 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
2821000
CY2013Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-84481000
CY2013Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
25340000
CY2013Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
38000
CY2013Q2 us-gaap Common Stock Value
CommonStockValue
236000
CY2013Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
234544000
CY2013Q2 us-gaap Liabilities
Liabilities
73274000
CY2013Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
2659000
CY2013Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
42878000
CY2013Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q2 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1253000
CY2013Q2 us-gaap Assets Current
AssetsCurrent
230526000
CY2013Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1503000
CY2013Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
228847000
CY2013Q2 us-gaap Assets
Assets
234544000
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
228847000
CY2013Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1679000
CY2013Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
9939000
CY2013Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2515000
CY2013Q2 blue Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
3409000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25604000
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
309000 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
309000 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.09
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2201000 shares
CY2012Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
6512000 shares
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2012Q4 us-gaap Liabilities Fair Value Disclosure Recurring
LiabilitiesFairValueDisclosureRecurring
215000
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
15267000
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2173000
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4628000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
-55747000
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-73354000
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
340000
CY2012Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
215000
CY2012Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
46000
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
69322000
CY2012Q4 us-gaap Liabilities
Liabilities
5229000
CY2012Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
340000
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q4 us-gaap Assets Current
AssetsCurrent
67784000
CY2012Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
250000
CY2012Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
67011000
CY2012Q4 us-gaap Assets
Assets
69322000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
67011000
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
773000
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1288000
CY2012Q4 blue Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
2115000
dei Trading Symbol
TradingSymbol
BLUE
dei Entity Registrant Name
EntityRegistrantName
bluebird bio, Inc.
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2013-06-30
dei Entity Central Index Key
EntityCentralIndexKey
0001293971
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segment
us-gaap Nature Of Operations
NatureOfOperations
<div> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>1.</b></font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Description of the business</b></font></td> </tr> </table> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">bluebird bio, Inc. (the &#x201C;Company&#x201D; or &#x201C;bluebird bio&#x201D;) was incorporated in Delaware on April&#xA0;16, 1992, and is headquartered in Cambridge, Massachusetts. The Company was formed to develop, manufacture and market therapies to safely and effectively deliver genes useful in the treatment of serious human diseases. Since its inception, the Company has devoted substantially all of its resources to its development efforts relating to its product candidates, including activities to manufacture product in compliance with good manufacturing practices (&#x201C;GMP&#x201D;), preparing to conduct clinical studies of its product candidates, providing general and administrative support for these operations and protecting its intellectual property.</font></p> </div>
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1244000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.65
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
57765000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-8.94
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.34
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1723000 shares
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M18D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
7000 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
27000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
3.05
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4440000 shares
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Use of estimates</i></b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas, among others: stock-based compensation expense, accrued expenses, valuation of warrants, revenue and income taxes.</font></p> </div>
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-22000
us-gaap Revenues
Revenues
7461000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
906000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11127000
us-gaap Contracts Revenue
ContractsRevenue
7291000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
281000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11127000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-452000
us-gaap Embedded Derivative No Longer Bifurcated Amount Reclassified To Stockholders Equity
EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity
655000
us-gaap Investment Income Interest
InvestmentIncomeInterest
10000
us-gaap Operating Income Loss
OperatingIncomeLoss
-10675000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-2000
us-gaap Increase In Restricted Cash
IncreaseInRestrictedCash
1253000
us-gaap Net Income Loss
NetIncomeLoss
-11127000
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
119841000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1265000
us-gaap License And Services Revenue
LicenseAndServicesRevenue
170000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
611000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
440000
us-gaap Costs And Expenses
CostsAndExpenses
18136000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5605000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
106589000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
65000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
67539000
us-gaap Share Based Compensation
ShareBasedCompensation
2318000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
161836000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1416000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2518000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
106180000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12531000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
65000
us-gaap Proceeds From Sale And Collection Of Notes Receivable
ProceedsFromSaleAndCollectionOfNotesReceivable
344000
us-gaap Depreciation
Depreciation
304000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
blue Net Income Loss Available To Common Stockholders
NetIncomeLossAvailableToCommonStockholders
-11127000
blue Stock Issued During Period Shares Stock Options Exercised1
StockIssuedDuringPeriodSharesStockOptionsExercised1
27000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
237000 shares
blue Deferred Stock Offering Costs Included In Accounts Payable And Accrued Liabilities
DeferredStockOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities
1259000
blue Change In Earnings Per Share Basic And Diluted
ChangeInEarningsPerShareBasicAndDiluted
-8.94
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10185000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-51.48
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12755000 shares
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
14000
us-gaap Revenues
Revenues
170000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
235000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9631000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
13000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12201000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
105000
us-gaap Investment Income Interest
InvestmentIncomeInterest
2000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9736000
us-gaap Increase In Restricted Cash
IncreaseInRestrictedCash
40000
us-gaap Net Income Loss
NetIncomeLoss
-9631000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
471000
us-gaap License And Services Revenue
LicenseAndServicesRevenue
170000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
517000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-89000
us-gaap Costs And Expenses
CostsAndExpenses
9906000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2694000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
8000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-170000
us-gaap Share Based Compensation
ShareBasedCompensation
385000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-7181000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1095000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
2996000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7212000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
8000
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
2570000
us-gaap Depreciation
Depreciation
133000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
3507000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
blue Change In Earnings Per Share Basic And Diluted
ChangeInEarningsPerShareBasicAndDiluted
-51.48
blue Net Income Loss Available To Common Stockholders
NetIncomeLossAvailableToCommonStockholders
-12201000
blue Stock Issued During Period Shares Stock Options Exercised1
StockIssuedDuringPeriodSharesStockOptionsExercised1
5000 shares
CY2013Q2 us-gaap Lessee Leasing Arrangements Operating Leases Term Of Contract
LesseeLeasingArrangementsOperatingLeasesTermOfContract
P9Y
CY2013Q2 us-gaap Lessee Leasing Arrangements Operating Leases Renewal Term
LesseeLeasingArrangementsOperatingLeasesRenewalTerm
P5Y
CY2013Q2 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2015-03-31
CY2013Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.0527 pure
CY2013Q2 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
209000
CY2013Q2 blue Letter Of Credit Related With New Lease Agreement
LetterOfCreditRelatedWithNewLeaseAgreement
1253000
CY2013Q2 blue Rent Abatement Credits
RentAbatementCredits
209000
CY2013Q2 blue Area Of Leased Space
AreaOfLeasedSpace
43600 sqft
CY2013Q2 blue Landlord Contribution For Leasehold Improvements
LandlordContributionForLeaseholdImprovements
6538000
CY2013Q2 us-gaap Embedded Derivative No Longer Bifurcated Amount Reclassified To Stockholders Equity
EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity
655000
CY2013Q2 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
104921000
CY2012Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
252000 shares
CY2012Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-23.21
CY2012Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12755000 shares
CY2012Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
6000
CY2012Q2 us-gaap Revenues
Revenues
85000
CY2012Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4563000
CY2012Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5848000
CY2012Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
37000
CY2012Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
1000
CY2012Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4600000
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
-4563000
CY2012Q2 us-gaap License And Services Revenue
LicenseAndServicesRevenue
85000
CY2012Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-30000
CY2012Q2 us-gaap Costs And Expenses
CostsAndExpenses
4685000
CY2012Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1331000
CY2012Q2 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
8000
CY2012Q2 us-gaap Share Based Compensation
ShareBasedCompensation
152000
CY2012Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3354000
CY2012Q2 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
1285000
CY2012Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2012Q2 blue Change In Earnings Per Share Basic And Diluted
ChangeInEarningsPerShareBasicAndDiluted
-23.21
CY2012Q2 blue Net Income Loss Available To Common Stockholders
NetIncomeLossAvailableToCommonStockholders
-5848000
CY2012Q2 blue Stock Issued During Period Shares Stock Options Exercised1
StockIssuedDuringPeriodSharesStockOptionsExercised1
5000 shares
CY2013Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2151000 shares
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.13
CY2013Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4440000 shares
CY2013Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
3000
CY2013Q2 us-gaap Revenues
Revenues
6334000
CY2013Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4583000
CY2013Q2 us-gaap Contracts Revenue
ContractsRevenue
6249000
CY2013Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4583000
CY2013Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-389000
CY2013Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
7000
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4194000
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-4583000
CY2013Q2 us-gaap License And Services Revenue
LicenseAndServicesRevenue
85000
CY2013Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
399000
CY2013Q2 us-gaap Costs And Expenses
CostsAndExpenses
10528000
CY2013Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3281000
CY2013Q2 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
31000
CY2013Q2 us-gaap Share Based Compensation
ShareBasedCompensation
1657000
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7247000
CY2013Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2013Q2 blue Change In Earnings Per Share Basic And Diluted
ChangeInEarningsPerShareBasicAndDiluted
-2.13
CY2013Q2 blue Net Income Loss Available To Common Stockholders
NetIncomeLossAvailableToCommonStockholders
-4583000
CY2013Q2 blue Stock Issued During Period Shares Stock Options Exercised1
StockIssuedDuringPeriodSharesStockOptionsExercised1
11000 shares

Files In Submission

Name View Source Status
0001193125-13-334653-index-headers.html Edgar Link pending
0001193125-13-334653-index.html Edgar Link pending
0001193125-13-334653.txt Edgar Link pending
0001193125-13-334653-xbrl.zip Edgar Link pending
blue-20130630.xml Edgar Link completed
blue-20130630.xsd Edgar Link pending
blue-20130630_cal.xml Edgar Link unprocessable
blue-20130630_def.xml Edgar Link unprocessable
blue-20130630_lab.xml Edgar Link unprocessable
blue-20130630_pre.xml Edgar Link unprocessable
d556541d10q.htm Edgar Link pending
d556541dex311.htm Edgar Link pending
d556541dex312.htm Edgar Link pending
d556541dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R1.xml Edgar Link unprocessable
R10.htm Edgar Link pending
R10.xml Edgar Link unprocessable
R11.htm Edgar Link pending
R11.xml Edgar Link unprocessable
R12.htm Edgar Link pending
R12.xml Edgar Link unprocessable
R13.htm Edgar Link pending
R13.xml Edgar Link unprocessable
R14.htm Edgar Link pending
R14.xml Edgar Link unprocessable
R15.htm Edgar Link pending
R15.xml Edgar Link unprocessable
R16.htm Edgar Link pending
R16.xml Edgar Link unprocessable
R17.htm Edgar Link pending
R17.xml Edgar Link unprocessable
R18.htm Edgar Link pending
R18.xml Edgar Link unprocessable
R19.htm Edgar Link pending
R19.xml Edgar Link unprocessable
R2.htm Edgar Link pending
R2.xml Edgar Link unprocessable
R20.htm Edgar Link pending
R20.xml Edgar Link unprocessable
R21.htm Edgar Link pending
R21.xml Edgar Link unprocessable
R22.htm Edgar Link pending
R22.xml Edgar Link unprocessable
R23.htm Edgar Link pending
R23.xml Edgar Link unprocessable
R24.htm Edgar Link pending
R24.xml Edgar Link unprocessable
R25.htm Edgar Link pending
R25.xml Edgar Link unprocessable
R26.htm Edgar Link pending
R26.xml Edgar Link unprocessable
R27.htm Edgar Link pending
R27.xml Edgar Link unprocessable
R28.htm Edgar Link pending
R28.xml Edgar Link unprocessable
R29.htm Edgar Link pending
R29.xml Edgar Link unprocessable
R3.htm Edgar Link pending
R3.xml Edgar Link unprocessable
R30.htm Edgar Link pending
R30.xml Edgar Link unprocessable
R31.htm Edgar Link pending
R31.xml Edgar Link unprocessable
R32.htm Edgar Link pending
R32.xml Edgar Link unprocessable
R33.htm Edgar Link pending
R33.xml Edgar Link unprocessable
R34.htm Edgar Link pending
R34.xml Edgar Link unprocessable
R35.htm Edgar Link pending
R35.xml Edgar Link unprocessable
R36.htm Edgar Link pending
R36.xml Edgar Link unprocessable
R37.htm Edgar Link pending
R37.xml Edgar Link unprocessable
R38.htm Edgar Link pending
R38.xml Edgar Link unprocessable
R39.htm Edgar Link pending
R39.xml Edgar Link unprocessable
R4.htm Edgar Link pending
R4.xml Edgar Link unprocessable
R5.htm Edgar Link pending
R5.xml Edgar Link unprocessable
R6.htm Edgar Link pending
R6.xml Edgar Link unprocessable
R7.htm Edgar Link pending
R7.xml Edgar Link unprocessable
R8.htm Edgar Link pending
R8.xml Edgar Link unprocessable
R9.htm Edgar Link pending
R9.xml Edgar Link unprocessable
report.css Edgar Link pending
Show.js Edgar Link pending